Landos Biopharma Inc

NASDAQ:LABP   3:53:38 PM EDT
0.95
-0.05 (-5.24%)
Products, Regulatory

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1B Trial

Published: 08/03/2022 12:56 GMT
Landos Biopharma Inc (LABP) - Landos Biopharma Reports Positive Top-line Results From Nx-13 Phase 1b Trial.
Landos Biopharma Inc - Nx-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-daily Doses.
Landos Biopharma Inc - Results Indicate Promising Early Signals Regarding Efficacy of Nx-13.
Landos Biopharma Inc - Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned.
Landos Biopharma Inc - Plans to Initiate a Phase 2 Clinical Trial to Evaluate Safety, Efficacy, and Optimal Dosing of Nx-13 in Uc Patients.